Location: Palo Alto, CA
CIK: 0001674712 · Show all filings
Period: Q4 2019 (← Previous) (Next →)
Filing Date: Feb 25, 2020
Total Value: $1.373B (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Aclaris Therapeutics, Inc. | 101,392,395 | $1B | 72.8% | $7.72 | — | 00461U105 | 000Common |
| — | Ascendis Pharma A/S | 2,552,237 | $299M | 21.8% | $81.47 | — | 04351P101 | 000000ADR |
| — | Galmed Pharmaceuticals Ltd | 9,610,156 | $47.33M | 3.4% | $5.02 | — | M47238106 | 000000SHS |
| — | Orchard Therapeutics plc | 2,805,035 | $26.63M | 1.9% | $7.99 | — | 68570P101 | 000000ADS |